<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054843</url>
  </required_header>
  <id_info>
    <org_study_id>Afamin in GDM</org_study_id>
    <nct_id>NCT04054843</nct_id>
  </id_info>
  <brief_title>Afamin in Gestational Diabetes Mellitus</brief_title>
  <official_title>Afamin Levels in First Trimester Pregnancies With Gestational Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etlik Zubeyde Han覺m Women's Health Care, Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etlik Zubeyde Han覺m Women's Health Care, Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study includes pregnancies in 11 to 14 th gestational weeks. Investigators will sample&#xD;
      maternal plasma in the first trimester and analyze maternal plasma afamin values. All these&#xD;
      women will then be screened by two step OGTT. Investigators will compare afamin levels in GDM&#xD;
      and control groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Gestational diabetes mellitus (GDM) is an endocrinopathy that occurs during&#xD;
      pregnancy, and presents several clinical findings together with increased blood glucose&#xD;
      levels. The frequency of GDM differs, while the incidence of the disease in Turkey is&#xD;
      reported to be 7%. Most of the societies recommend screening all women with or without any&#xD;
      risk factors in terms of GDM. The definitive diagnosis is made via oral glucose challenge&#xD;
      test (OGTT). Early diagnosis and treatment are the key points to improve maternal and fetal&#xD;
      outcomes. Different biomarkers are studied regarding GDM diagnosis starting from first&#xD;
      trimester. However, there is not a worldwide accepted biomarker for defining the high risk&#xD;
      group to the date. Afamin is known as an important indicator of oxidative stress. Moreover,&#xD;
      oxidative stress itself is strongly associated with insulin resistance and obesity which are&#xD;
      responsible from GDM pathogenesis.&#xD;
&#xD;
      Objective To investigate the association between first trimester maternal plasma afamin&#xD;
      levels and GDM. Also, investigators aimed to understand the role of afamin for the prediction&#xD;
      of GDM in this study.&#xD;
&#xD;
      Methods This is an observational prospective cohort study conducted in Department of&#xD;
      Perinatology, Etlik Zubeyde Hanim Women's Health Care, Training and Research Hospital,&#xD;
      University of Health Sciences, Ankara, Turkey. During 11 and 14 weeks of gestational,&#xD;
      maternal blood will be obtained from eligible pregnant women, and samples will be stored at&#xD;
      -80 oC. Informed written consent will be obtained from participants. Between 24th and 28th&#xD;
      gestational weeks, all these women will be screened by two step OGTT. Then, afamin levels&#xD;
      will be compared in GDM and control groups. Exclusion criteria are; multiple pregnancy, fetal&#xD;
      anomalies, pregestational diabetes, underlying chronic diseases (hypertension, thyroid&#xD;
      dysfunction, other endocrinopathies, autoimmune disorders), age &lt;18 or &gt; 35 years, fasting&#xD;
      glucose level &gt; 105 mg/dL or random glucose level &gt; 200 mg/dL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">March 15, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal plasma afamin levels In first trimester GDM prediction</measure>
    <time_frame>6 months</time_frame>
    <description>The predictive value of first trimester maternal plasma afamin levels for the diagnosis of gestational diabetes mellitus in comparison with two step OGTT</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Gestational diabetes mellitus</arm_group_label>
    <description>First trimester pregnancies with gestational diabetes mellitus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>First trimester healthy pregnancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Afamin</intervention_name>
    <description>Plasma maternal afamin levels</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Gestational diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women within 11 and 14 weeks of gestational weeks&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  singleton pregnancy,&#xD;
&#xD;
          -  having no fetal anomalies&#xD;
&#xD;
          -  having no pregestational diabetes&#xD;
&#xD;
          -  having no underlying chronic diseases (hypertension, thyroid dysfunction, other&#xD;
             endocrinopathies, autoimmune disorders)&#xD;
&#xD;
          -  age &gt;18 or &lt; 35 years&#xD;
&#xD;
          -  fasting glucose level &lt; 105 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple pregnancy&#xD;
&#xD;
          -  fetal anomalies&#xD;
&#xD;
          -  pregestational diabetes&#xD;
&#xD;
          -  underlying chronic diseases (hypertension, thyroid dysfunction, other&#xD;
             endocrinopathies, autoimmune disorders)&#xD;
&#xD;
          -  age &lt;18 or &gt; 35 years&#xD;
&#xD;
          -  fasting glucose level &gt; 105 mg/dL or random glucose level &gt; 200 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Etlik Zubeyde Han覺m Women's Health Care, Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Etlik Zubeyde Han覺m Women's Health Care, Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Aykan Yucel, Professor, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

